Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2003

01-01-2003 | Review Article

Highlights of the 15th Annual Congress of the European Association of Nuclear Medicine, Vienna, 2002

Author: Markus Schwaiger

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2003

Login to get access

Excerpt

The 15th congress of the European Association of Nuclear Medicine, which took place in Vienna at the Austria Convention Center from 31 August to 4 September 2002, was well organised. The excellent infrastructure at the centre guaranteed a successful meeting, and Vienna again proved to be an entertaining congress city. …
Literature
1.
Maisey MN. Clinical PET in Europe: present status and developments. Eur J Nucl Med 2002; 29 Suppl 1:S61 (abstract 55b).
2.
von Schulthess G. PET/CT: the best of both worlds. Eur J Nucl Med 2002; 29 Suppl 1:S62 (abstract 55c).
3.
Bruin NM, Pijpers R, Buist MR, Verheijen RHM, Baumann E, Teule GJJ. Feasibility of laparoscopic gamma probe detection of sentinel lymph nodes in patients with cervical cancer. Eur J Nucl Med 2002; 29 Suppl 1:S63 (abstract 57)
4.
Gratz S, Rennen HJJM, Boerman OC, Oyen WJG. In vitro granulocyte stimulation: the innate immune system cannot be mimicked. Eur J Nucl Med 2002; 29 Suppl 1:S70 (abstract 87).
5.
Juengling FD, Karitzky J, Solbach C, Kassubek J, Saft C, Heinen B, Kioschies T, Reske SN. Combined [11C]raclopride-PET and voxel based morphometry analysis in early Huntington's disease: separating between functional and morphological alterations. Eur J Nucl Med 2002; 29 Suppl 1:S86 (abstract 148).
6.
Visvikis D, Costa DC, Croasdale I, Ell PJ. CT based attenuation correction in the calculation of SUVs for 18FDG-PET. Eur J Nucl Med 2002; 29 Suppl 1:S108 (abstract 226).
7.
Mawlawi O, Macapinlac H, Erasmus J, Krugh K, Cody D, Forster K, Chasen M. Transformation of CT numbers to PET attenuation factors in the presence of iodinated IV contrast. Eur J Nucl Med 2002; 29 Suppl 1:S108 (abstract 227).
8.
Peter J, Saffrich R, Semmler W. Simultaneous simulation of isotopic and optical photons for micro-tomographic imaging approaches. Eur J Nucl Med 2002; 29 Suppl 1:S79 (abstract 116).
9.
Ravasi L, Shimoji K, Jagoda EM, Kiesewetter DO, Eckelman WC. Is internalization responsible for M2 selectivity of FP-TZTP? Eur J Nucl Med 2002; 29 Suppl 1:S379 (P_731).
10.
Schirrmacher R, Muehlhausen U, Waengler B, Schirrmacher E, Reinhard J, Kaina B, Roesch F. Synthesis and evaluation of new glucose conjugated O 6-methyl-guanine-DNA methyltransferase (MGMT) inhibitors for in vivo determination of MGMT-status in tumour tissue. Eur J Nucl Med 2002; 29 Suppl 1:S371 (P_702).
11.
Mitterhauser M, Dobrozemsky G, Wadsak W, Zettinig G, Viernstein H, Zolle I, Kletter K, Dudczak R. ( R)-[ O -methyl-11C]metomidate may be superior to [18F]-FDG for PET imaging of metastases from adrenocortical origin. Eur J Nucl Med 2002; 29 Suppl 1:S372 (abstract P_703).
12.
Minn H, Salonen A, Friberg J, Någren K, Roivainen A, Yu M, Teräs M, Långsjö J, Nuutila P. Characterization of adrenal masses with 11C-metomidate and PET. Eur J Nucl Med 2002; 29 Suppl 1:S117 (abstract 259).
13.
Krasikova R, Zaitsev V, Kuznetsova O, Fedorova O, Mosevich I, Ametamey SM, Belokon Y, Vyskocil S, Schubiger PA. New phase-transfer catalytic synthesis of 2-18F-fluoro- l -tyrosine for PET. Eur J Nucl Med 2002; 29 Suppl 1:S76 (abstract 108).
14.
Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106:653–658.CrossRefPubMed
15.
Khorsand A, Garf S, Pirich CH, Zettinig G, Eidherr H, Kletter K, Sochor H, Maurer G, Porenta G. Assessment of myocardial perfusion. Eur J Nucl Med 2002; 29 Suppl 1:S176 (abstract 477).
16.
Wielepp JP, Baller D, Kammeier A, Pulawski E, Weise R, Burchert W. Improvement of myocardial perfusion after lipid-lowering therapy in patients with coronary atherosclerosis. Eur J Nucl Med 2002; 29 Suppl 1:S222 (P_132).
17.
Schelbert H. The role of nuclear medicine in the detection of pre-clinical coronary atherosclerosis. Eur J Nucl Med 2002; 29 Suppl 1:S110 (abstract 231c).
18.
Knuuti J, Stolen K, Kemppainen J, Kalliokoski K, Hällsten K, Salo T, Airaksinen J, Nuutila P. Influence of biventricular oxidative metabolism on exercise capacity in patients with dilated cardiomyopathy. Eur J Nucl Med 2002; 29 Suppl 1:S66 (abstract 71).
19.
Knuuti J, Stolen K, Kemppainen J, Kalliokoski K, Ukkonen H, Salo T, Airaksinen J, Nuutila P. Exercise training improves left ventricular efficiency and decreases biventricular oxidative metabolism in patients with dilated cardiomyopathy. Eur J Nucl Med 2002; 29 Suppl 1:S66 (abstract 72).
20.
Bennink RJ, van den Hoff MJ, van Hemert FJ, de Bruin CM, Spijkerboer AL, van Eck-Smit BL. Annexin-V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. Eur J Nucl Med 2002; 29 Suppl 1:S49 (abstract 10).
21.
Thimister PWL, Pakbiers M, Janssen D, Heidendal GAK. Disappearance of apoptosis in the subacute phase of acute myocardial infarction. Eur J Nucl Med 2002; 29 Suppl 1:S49 (abstract 9).
22.
Brenner W, Aicher A, Zuhayra M, Massoudi S, Badorff C, Czech N, Zeiher AM, Dimmeler S, Henze E. In vivo monitoring of indium-111-labeled endothelial progenitor cells in a rat myocardial infarction model. Eur J Nucl Med 2002; 29 Suppl 1:S50 (abstract 12).
23.
Plotkin M, Amthauer H, Lüdermann L, Merschhemke M, Gutberlet M, Meencke HJ, Felix R, Venz S. Statistical parametric mapping of cerebral glucose metabolism in frontal lobe epilepsy. Eur J Nucl Med 2002; 29 Suppl 1:S71 (abstract 92).
24.
Benti R, Mariani C, Antonini A, De Notaris R, Ferrari M, Landi A, Gaini SM, Pezzoli G, Gerundini P. r-CBF brain SPET before surgery and during subthalamic nuclei (STN) high frequency stimulation (DBS) in Parkinson's disease. Eur J Nucl Med 2002; 29 Suppl 1:S151 (abstract 387).
25.
Catafau AM, Tolosa E. Clinical impact of dopamine transporter SPECT using 123I-ioflupane (DaTSCANTM) in uncertain parkinsonian syndromes. Eur J Nucl Med 2002; 29 Suppl 1:S102 (abstract 206).
26.
Santiago-Ribeiro MJ, Cochen V, Nguyen JP, Loc'h C, Defer G, Peschanski M, Hantraye P, Cesaro P, Remy P. Clinical and PET recovery after neuronal graft in Parkinson's disease (PD) depend on the number of fetal donors. Eur J Nucl Med 2002; 29 Suppl 1:S87 (abstract 150).
27.
Santiago-Ribeiro MJ, Vidailhet M, Douaud G, Trébossen R, Hantraye P, Remy P. Parkinson's disease progresses more rapidly in the primarily more affected striatum: an 18F-DOPA PET study. Eur J Nucl Med 2002; 29 Suppl 1:S87 (abstract 151).
28.
Halldin C, Tarkiainen J, Sovago J, Vercouillie J, Gulyas B, Guilloteau D, Emond P, Hiltunen J, Farde L. Carbon-11 labeled DADAM—a serotonin transporter PET radioligand with a fast equilibrium. Eur J Nucl Med 2002; 29 Suppl 1:S120 (abstract 268).
29.
Halldin C. The role of nuclear medicine in the development of new drugs. Eur J Nucl Med 2002; 29 Suppl 1:S110 (abstract 231b).
30.
Ahonen AK, Kauppinen TA, Heikman P, Bergström KA, Nikkinen P, Kyllönen T, Kämäräinen E-L, Puronto O, Hiltunen J. Imaging of serotonin transporters in human beings using I-123 ADAM. Eur J Nucl Med 2002; 29 Suppl 1:S120 (abstract 269).
31.
Helmuth L. Long-awaited technique spots Alzheimer's toxin. Science 2002; 297:752–753.
32.
Vanderghinste D, Vaneeckhoudt M, Bormans G, Verbruggen A. Synthesis and preliminary evaluation of two fluorine-18 labelled thioflavine T derivatives as potential tracer agents for visualisation of amyloid beta. Eur J Nucl Med 2002; 29 Suppl 1:S58 (abstract 45).
33.
Wyper D, Chisholm J, Patterson J, Owens J, Pimlott S, Brown D. Acetylcholine receptors and response to cholinesterase inhibition in Alzheimer's disease. Eur J Nucl Med 2002; 29 Suppl 1:S73 (abstract 98).
34.
Frey KA, Koeppe RA, Little R, An H, Junck L, Heumann M, Gilman S. VMAT2 PET imaging distinguishes Alzheimer's disease and dementia with Lewy bodies. Eur J Nucl Med 2002; 29 Suppl 1:S152 (abstract 389).
35.
Gallowitsch HJ, Konstantiniuk P, Jörg L, Gebhard B, Haid A, Roka S, Schrenk P, Tausch C, Urbania A. SLN-biopsy in breast cancer. The Austrian experience with a multi-center data-base project (MCDBP). Eur J Nucl Med 2002; 29 Suppl 1:S51 (abstract 15).
36.
Cortes M, Fernandez A, Escobedo A, Azpeitia D, Benito E, Prieto L, Moreno A, Ricart Y, Martin-Comin J. Sentinel node (SN) radionuclide localization in breast cancer patients treated with neoadjuvant chemotherapy. Eur J Nucl Med 2002; 29 Suppl 1:S52 (abstract 20).
37.
Pons F, Vidal-Sicart S, Puig S, Ortega M, Martin F, Vilalta A, Rull R, Palou J, Castel T. Detection of occult metastases in the sentinel lymph node by reverse transcriptase-polymerase chain reaction (RT-PCR) in early-stage melanoma patients. Eur J Nucl Med 2002; 29 Suppl 1:S250 (P_236).
38.
von Schulthess G. PET/CT: the best of both worlds. Eur J Nucl Med 2002; 29 Suppl 1:S62 (abstract 55c).
39.
Burger I, von Schulthess K, Goerres GW, Hany TF. Diagnostic improvement of PET-CT in recurrent colorectal carcinoma compared to PET alone. Eur J Nucl Med 2002; 29 Suppl 1:S47 (abstract 1).
40.
Van Tinteren H, Hoekstra OS, Smit EF, Van den Bergh JH, Schreurs AJ, Stallaert RA, Van Velthoven PC, Comans EF, Diepenhorst FW, Verboom P, Van Mourik JC, Postmus PE, Boers M, Teule GJ. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung canger: the PLUS multicentre randomised trial. Lancet 2002;359:1361–1362.CrossRefPubMed
41.
Verboom P, Grijseels EWM, Hoekstra OS, van Tinteren H. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med 2002; 29 Suppl 1:S174 (abstract 472).
42.
Lomena F, Simo M, Setoain X, Pérez G, Garcia JR, Costansa JM, Carrio I, Setoain J,. Domenech-Torne FM. Whole-body 18F-FDG PET in patients with suspected recurrence of breast cancer. Eur J Nucl Med 2002; 29 Suppl 1:S47 (abstract 3).
43.
Schot BW, Pruim J, van Imhoff GW, Sluiter W, Vellenga E, Vaalburg W. Early FDG-PET for the prediction of long-term treatment outcome in chemo-sensitive relapsed lymphoma. Eur J Nucl Med 2002; 29 Suppl 1:S113 (abstract 243).
44.
Buck AK, Hetzel M, Scirrmeister H, Halter G, Glatting G, Juengling FD, Kotzerke J, Neumaier B, Reske SN. [18F]FLT and [18F]FDG-PET for assessment of pulmonary nodules. Eur J Nucl Med 2002; 29 Suppl 1:S79 (abstract 121).
45.
Visvikis D, Francis DL, Costa DC, Mulligan R, Townsend C, Taylor I, Ell PJ. Quantitative comparison of 18FDG and 18FLT in colorectal carcinoma. Eur J Nucl Med 2002; 29 Suppl 1:S79 (abstract 122).
46.
Palmedo H, Textor J, Ko Y, Grohé C, Von Mallek D, Bender H, Ezziddin S, Reinhardt MJ, Biersack HJ. PET with F-18 fluoride compared to bone scintigraphy in the diagnosis of bone metastases: results of a prospective study. Eur J Nucl Med 2002; 29 Suppl 1:S47 (abstract 4).
47.
Pauleit D, Langen KJ, Floeth F, Sabel M, Felsberg J, Reifenberger G, Hamacher K, Coenen HH. Improved delineation of tumor tissue using FET PET compared with MRI in cerebral gliomas? Eur J Nucl Med 2002; 29 Suppl 1:S80 (abstract 126).
48.
Zimny M, Gagel B, DiMartino E, Cremerius U, Reinartz P, Hamacher K, Coenen HH, Eble M, Buell U. Fluorine-18 fluoromisonidazole to detect hypoxia in head and neck cancer—a comparison with tissue oxygenation determined by PO2-polarography. Eur J Nucl Med 2002; 29 Suppl 1:S174 (abstract 470).
49.
Lehtiö K, Oikonen V, Nyman S, Grönroos T, Roivainen A, Eskola O, Minn H. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using tumour-to-plasma ratio. Eur J Nucl Med 2002; 29 Suppl 1:S174 (abstract 471).
50.
De Vincentis G, Scopinaro F, Varvarigou A, Iori F, D'Amico F, Laurenti C, Manganaro L, Paolozzi A. 13 Leu 99m Tc bombesin detects primary prostate cancer. Eur J Nucl Med 2002; 29 Suppl 1:S68 (abstract 79).
51.
Brouwers AH, Van Eerd JEM, Oosterwijk E, Oyen WJG, Corstens FHM, Boerman OC. Experimental radioimmunotherapy against renal cell carcinoma using cG250 labelled with 131-I, 90-Y, 177-Lu and 186-Re. Eur J Nucl Med 2002; 29 Suppl 1:S118 (abstract 261).
52.
de Jong M, Bernard HF, Breeman WAP, Bijster M, van den Berg R, van Gameren A, Krenning EP. Combined use of 90Y- and 177Lu-labelled somatostatin analogues for radionuclide therapy. Eur J Nucl Med 2002; 29 Suppl 1:S119 (abstract 264).
53.
Kwekkeboom DJ, Kam BL, Bakker WH, Kooij PPM, Teunissen JJM, de Herder WW, van Eijck CHJ, de Jong M. Treatment with [Lu-177-DOTA,Tyr3]octreotate in patients with somatostatin receptor-positive GEP-tumors. Eur J Nucl Med 2002; 29 Suppl 1:S101 (abstract 199).
54.
de Jong M. Radiolabelled peptides: present status and future directions. Eur J Nucl Med 2002; 29 Suppl 1:S141 (abstract 349d).
55.
Barbet J, Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Devillers A, Chang K, Goldenberg DM, Chatal JF. Pharmacokinetics and dosimetry of anti-CEA x anti-hapten bispecific antibody (BsMAb) and iodine-131-labeled hapten in pretargeted radioimmunotherapy patients. Eur J Nucl Med 2002; 29 Suppl 1:S149 (abstract 379).
56.
Hampl H, Seidl C, Abend M, Becker K-F, Apostolidis C, Carlos-Marquez R, Schwaiger M, Senekowitsch-Schmidtke R. Selective killing of fibroblasts expressing a tumor-specific antigen by a Bi-213 conjugated antibody. Eur J Nucl Med 2002; 29 Suppl 1:S313 (P_480).
57.
Capello A, Breeman WAP, Bernard HF, van Hagen PM, Srinivasan A, Krenning EP, de Jong M. RGD-DTPA-octreotate for radionuclide therapy of somatostatin receptor-positive tumours. Eur J Nucl Med 2002; 29 Suppl 1:S119 (abstract 265).
58.
Kampen WU, Godbersen GS, Czech N, Besch OF, Brenner W, Muhle C, Henze E. Radio-tympano-sinu-orthesis with Re-186-colloid: a new treatment modality for chronic otitis media and sinusitis. Eur J Nucl Med 2002; 29 Suppl 1:S180 (abstract 495).
59.
Zinn KR, LoBuglio AF, Cao Z, Chaudhuri TR. Non-invasive optical imaging of angiogenesis in breast cancer xenografts during therapy. Eur J Nucl Med 2002; 29 Suppl 1:S178 (abstract 486).
60.
Peñuelas I, Boán JF, Narvaiza I, Barajas MA, Martí-Climent JM, Rodríguez-Fraile M, Prieto J, Richter JA. Can PET be used for in-vivo imaging of low doses of an adenoviral vector administered by direct intraportal injection? Eur J Nucl Med 2002; 29 Suppl 1:S106 (abstract 218).
61.
Ottobrini L, Ciana P, Gambhir SS, Comi P, Biserni A, Maggi A, Lucignani G. Development of a bicistronic vector for concurrent radionuclide and bioluminescent optical imaging of reporter gene expression. Eur J Nucl Med 2002; 29 Suppl 1:S106 (abstract 220).
Metadata
Title
Highlights of the 15th Annual Congress of the European Association of Nuclear Medicine, Vienna, 2002
Author
Markus Schwaiger
Publication date
01-01-2003
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2003
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-002-1053-5

Other articles of this Issue 1/2003

European Journal of Nuclear Medicine and Molecular Imaging 1/2003 Go to the issue

Original Article

Anatomically standardised 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease

Erratum

PET study of the [11C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow

Short Communication

Cerebral haemodynamics in patients with hydrocephalus after subarachnoid haemorrhage due to ruptured aneurysm

Original Article

Clinical validation of simultaneous dual-isotope myocardial scintigraphy

Original Article

PET-MR image fusion in soft tissue sarcoma: accuracy, reliability and practicality of interactive point-based and automated mutual information techniques

Short Communication

[N-methyl 11C]meta-Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy